文献速递冠心病外科

糖尿病患者多支动脉移植的生存获益:一项20年全国经验

Survival of multiple arterial grafting in diabetic populations: a 20-year national experience.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

该回顾性分析基于澳大利亚与新西兰心胸外科数据库2001年6月至2020年1月数据,在倾向性评分1:1匹配的17474对非糖尿病和10989对糖尿病患者中比较多支动脉移植与单支动脉移植,中位随访5.9年时多支动脉移植的全因死亡风险在糖尿病组(HR 0.83,95%CI 0.76-0.90,P<0.001)和非糖尿病组(HR 0.88,95%CI 0.82-0.95,P<0.001)均显著低于单支动脉移植。

要点

  • 多支动脉移植较单支动脉移植与糖尿病患者更好的长期生存相关(HR 0.83,95%CI 0.76-0.90,P<0.001)。
  • 非糖尿病患者的生存获益方向一致(HR 0.88,95%CI 0.82-0.95,P<0.001)。
  • 糖尿病对多支动脉移植生存优势的交互作用不显著(P=0.55)。

核心结论

  • 多支动脉移植与非糖尿病和糖尿病患者较单支动脉移植改善的总生存相关。

研究设计与样本

  • 回顾性分析澳大利亚与新西兰心胸外科数据库2001年6月至2020年1月行首次孤立冠状动脉旁路移植术的患者,按静脉桥数量无关分为单支或多支动脉移植,采用1:1倾向性评分匹配比较。
  • 匹配后生成17474对非糖尿病和10989对糖尿病患者,中位随访5.9年(四分位距3.2-9.6年)。

主要发现

  • 糖尿病组多支动脉移植较单支动脉移植的全因死亡风险显著降低(HR 0.83,95%CI 0.76-0.90,P<0.001)。
  • 非糖尿病组多支动脉移植较单支动脉移植的全因死亡风险显著降低(HR 0.88,95%CI 0.82-0.95,P<0.001)。
  • 30天心肌梗死发生率单支动脉移植高于多支动脉移植,糖尿病组P=0.029,非糖尿病组P<0.001。
  • 糖尿病对多支动脉移植生存优势的交互作用不显著(P=0.55)。
  • 按糖尿病管理方式进一步分层结果一致。

关键数值与推荐

  • 全因死亡风险比:糖尿病组多支动脉移植vs单支动脉移植HR 0.83(95%CI 0.76-0.90,P<0.001)。
  • 全因死亡风险比:非糖尿病组多支动脉移植vs单支动脉移植HR 0.88(95%CI 0.82-0.95,P<0.001)。
  • 30天心肌梗死发生率比较:糖尿病组单支vs多支P=0.029,非糖尿病组单支vs多支P<0.001。
  • 糖尿病与多支动脉移植疗效的交互作用P=0.55。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Diabetics may have diminished survival after coronary artery bypass grafting even with multiple arterial revascularization. We compared multi-arterial versus single-arterial grafting (SAG) survival in diabetic and non-diabetic patients undergoing primary isolated bypass surgery. METHODS: This is a retrospective analysis of the Australian and New Zealand Society of Cardiac-Thoracic Surgical Database from June 2001 to January 2020. Patients were classified as having either single or multiple arterial grafting irrespective of the number of venous grafts. The end points were long-term all-cause mortality and 30-day clinical outcomes, which was compared in 1:1 propensity score-matched patients. Cox regression model was used to assess interactions between diabetes and the treatment effect of multi-arterial grafting, reported as hazard ratios (HRs) and confidence intervals (CIs). Short-term outcomes were compared with McNemar's paired t-test. RESULTS: From 69 624 patients, matching generated 17 474 non-diabetic and 10 989 diabetic patient pairs. At a median [interquartile range] of 5.9 [3.2-9.6] years postoperative, mortality was significantly lower after multi-arterial grafting for both diabetic (HR, 0.83; 95% CI, 0.76-0.90, P < 0.001) and non-diabetic (HR, 0.88; 95% CI, 0.82-0.95; P < 0.001) cohorts than SAG. The incidence of 30-day myocardial infarction was significantly higher in single than multiple arterial grafting for both cohorts (diabetic, P = 0.029; non-diabetic, P < 0.001). The interaction analysis suggested an insignificant effect of diabetes (P = 0.55) on the observed survival advantage. Further stratification by diabetic management generated consistent results. CONCLUSIONS: Multi-arterial grafting was associated with improved overall survival compared to SAG for both non-diabetic and diabetic patients.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Ren J, Royse C, Tian DH, et al. Survival of multiple arterial grafting in diabetic populations: a 20-year national experience. Eur J Cardiothorac Surg. 2023. PMID: 36924418. doi:10.1093/ejcts/ezad091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。